Skip to content

GLP-1 calculator

Zepbound Weight Loss Calculator

Enter your weight and goal to see what the Zepbound trials found on 5, 10 and 15 mg: the average loss, the spread across 100 people, and how many reached a goal like yours. Mounjaro is the same medicine.

Updated

Used to show how many people in the trial got that far.

Quick answer

In SURMOUNT-1, adults without diabetes lost 15.0% of their body weight on average after 72 weeks on Zepbound 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. With type 2 diabetes, in SURMOUNT-2, they lost 12.8% on 10 mg and 14.7% on 15 mg. On 15 mg, 56.7 in 100 people lost 20% or more.

What each medicine did in its trial

Medicine and doseTrialAverage weight lostLost 10% or moreLost 20% or more
Zepbound / Mounjaro 5 mgSURMOUNT-172 weeks15%placebo: 3.1%69 in 10030 in 100
Zepbound / Mounjaro 10 mgSURMOUNT-172 weeks19.5%placebo: 3.1%78 in 10050 in 100
Zepbound / Mounjaro 10 mgwith type 2 diabetesSURMOUNT-272 weeks12.8%placebo: 3.2%61 in 10022 in 100
Zepbound / Mounjaro 15 mgSURMOUNT-172 weeks20.9%placebo: 3.1%84 in 10057 in 100
Zepbound / Mounjaro 15 mgwith type 2 diabetesSURMOUNT-272 weeks14.7%placebo: 3.2%65 in 10031 in 100

Log your weight next to your doses

In Mingo you set a weight goal and the weekly pace you're aiming for, see your estimated goal date, and watch each weigh-in on a chart marked with every dose change.

Rated 4.7 out of 5 on the App Store · 1,579 ratings

Where the numbers come from

Every number here is copied from section 14 of the current US Zepbound prescribing information. For each dose it takes the average weight lost, the share of people who lost at least 5, 10, 15 and 20%, and the placebo group, and multiplies your weight by them. The label counts everyone who started the trial, whether or not they kept taking it. Some websites quote bigger numbers from a second analysis that only counts people who stayed on the medicine, and some mix the two; we don’t.

Zepbound dose Trial Average loss On placebo Lost 20% or more
5 mg SURMOUNT-1, 72 weeks 15.0% 3.1% 30.0 in 100
10 mg SURMOUNT-1, 72 weeks 19.5% 3.1% 50.1 in 100
15 mg SURMOUNT-1, 72 weeks 20.9% 3.1% 56.7 in 100
10 mg, type 2 diabetes SURMOUNT-2, 72 weeks 12.8% 3.2% 21.5 in 100
15 mg, type 2 diabetes SURMOUNT-2, 72 weeks 14.7% 3.2% 30.8 in 100

Zepbound and Mounjaro

Zepbound and Mounjaro are both tirzepatide, made by Lilly, at the same doses. In the US, Zepbound’s label covers weight management and Mounjaro’s covers type 2 diabetes, which is why this calculator uses Zepbound’s trials. In the UK and EU, Mounjaro is also authorised for weight management, and the same SURMOUNT trials apply.

The dose steps come first

Everyone starts at 2.5 mg and steps up by 2.5 mg no sooner than every four weeks. The trial groups reached 5 mg in week 5, 10 mg in week 13 and 15 mg in week 21, then stayed there. So the scale often moves slowly in the first two months. The Zepbound dosage chart shows every step.

The label reports weight at the end of the trial, not week by week, so this calculator doesn’t draw a curve. One marker: in SURMOUNT-4, people had lost 20.9% after 36 weeks on the highest dose they could tolerate (Aronne et al., JAMA 2024).

Is your goal realistic on Zepbound?

The calculator compares your goal with how many people in the trial reached it. On 15 mg, 83.5 in 100 lost at least 10% and 56.7 in 100 lost 20% or more; on 5 mg, those numbers were 68.5 and 30.0. If you don’t have a goal yet, the ideal weight calculator shows the healthy BMI range for your height and 5, 10 and 15% steps on the way.

Staying on it

In SURMOUNT-4, people who switched to placebo regained 14.0% of their weight over the next year, while those who stayed on lost another 5.5% (Aronne et al., JAMA 2024). The label describes Zepbound as a treatment for chronic weight management. To compare with semaglutide, see the Wegovy weight loss calculator or the GLP-1 weight loss calculator.

Track it against the trial

In Mingo you log each Zepbound or Mounjaro dose and every weigh-in on one chart that marks each dose change, so you can see how your own numbers compare with the trial and show your doctor.

Frequently asked questions

How much weight will I lose on Zepbound?

Nobody can predict it for one person. In SURMOUNT-1, adults without diabetes lost 15.0%, 19.5% and 20.9% on average after 72 weeks on 5, 10 and 15 mg. On 15 mg, 90.9 in 100 lost at least 5% and 56.7 in 100 lost 20% or more.

Is Mounjaro the same as Zepbound for weight loss?

They're the same medicine, tirzepatide, at the same doses. In the US, Zepbound is approved for weight management and Mounjaro for type 2 diabetes, so the weight-loss numbers come from Zepbound's label. In the UK and EU, Mounjaro is also authorised for weight management.

Which dose of Zepbound gives the most weight loss?

In SURMOUNT-1, the 15 mg group lost the most, 20.9% on average, against 19.5% on 10 mg and 15.0% on 5 mg. Everyone started at 2.5 mg and stepped up by 2.5 mg every 4 weeks. Your doctor sets the dose that works for you, and many people stay on a lower one.

How much weight do you lose on Zepbound in the first month?

The first month is on 2.5 mg, a starting dose that the label says is not for weight management, so most of the loss comes later. In SURMOUNT-4, people had lost 20.9% after 36 weeks on the highest dose they could tolerate.

Why do people with type 2 diabetes lose less?

In SURMOUNT-2, adults with type 2 diabetes lost 12.8% on 10 mg and 14.7% on 15 mg after 72 weeks, against 3.2% on placebo. That trial had no 5 mg group. Tick the diabetes box to see those numbers.

What happens if I stop Zepbound?

In SURMOUNT-4, people who switched to placebo after 36 weeks regained 14.0% of their weight over the next year, while those who stayed on lost another 5.5%. Talk to your doctor before stopping or lowering your dose.

Is Zepbound better than Wegovy for weight loss?

In SURMOUNT-5, the one head-to-head trial, adults without diabetes on the highest tolerated dose of tirzepatide lost 20.2% after 72 weeks, against 13.7% on semaglutide. Side effects, cost and coverage matter too.

Sources

Updated .

  1. Zepbound prescribing information, revised 8/2026, section 14, Table 2 (DailyMed)
  2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022
  3. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA 2024
  4. Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025

GLP-1 calculators and dose charts